Fulzerasib plus cetuximab in first-line KRASG12C-mutated nonsmall-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
Por:
Gregorc, V, Majem, M, Lo Russo, G, Maio, M, Salvagni, S, Gutiérrez-Calderon, V, Gonzalez-Cao, M, Contreras, SS, Koumarianou, A, Bearz, A, Bernabé-Caro, R, Viteri, S, de Sanmamed, MF, Zagouri, F, Bueno, TM, Lazzari, C, Martínez-Recio, S, Giménez-Capitán, A, Zhang, Y, Shan, Y, Zhu, HQ, Zhao, CQ, Shen, HG, Wang, Y and Rosell, R
Publicada:
1 abr 2026
Ahead of Print:
1 mar 2026
Resumen:
Background Fulzerasib, a KRASG12C inhibitor, has shown clinical activity in previously treated non-small-cell lung cancer (NSCLC). Clinical studies indicate that combining a KRASG12C inhibitor with an anti-EGFR antibody is effective in colorectal cancer; however, its benefit in NSCLC remains to be explored. Methods This single-arm, phase 1b/2 trial enrolled patients at 30 medical centres in Spain, Italy, and Greece. Eligible patients had KRASG12C-mutated NSCLC with no previous systemic anti-tumour therapy for advanced or metastatic disease and were aged 18 years and older; had at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1; had an Eastern Cooperative Oncology Group performance status of 0 or 1; and had a life expectancy of 3 months or more. Enrolled patients received 600 mg oral fulzerasib twice daily plus 500 mg/m2 intravenous cetuximab every 2 weeks. The primary endpoint was investigator-assessed objective response rate per RECIST 1.1 assessed in the full response analysis set. The study was registered with ClinicalTrials.gov (NCT05756153) and is complete. Findings Between April 23, 2023, and April 15, 2024, a total of 60 patients were screened, and 47 patients (78%) received treatment. The median age was 68 years (IQR 59-72); 25 patients (53%) were male and 22 (47%) were female. 45 (95%) patients were current or former smokers. As of Jan 14, 2025, the median follow-up time and treatment duration were 12 & centerdot;8 months (90% CI 11 & centerdot;6-14 & centerdot;6) and 10 & centerdot;1 months (IQR 6 & centerdot;3-13 & centerdot;0) months, respectively. The confirmed objective response rate was 69% (90% CI 56-80). Treatment-related adverse events (TRAEs) occurred in 41 (87%) of the 47 patients (grade 3 in seven [15%]). No grade 4 or 5 TRAEs were observed. TRAEs led to drug discontinuation in three (6%) patients, with only cetuximab being discontinued. Interpretation In treatment-naive KRASG12C-mutated NSCLC, fulzerasib plus cetuximab showed encouraging activity with a favourable safety profile. The combination is currently being planned for investigation in a phase 3 study. Funding Zhejiang GenFleet Therapeutics. Copyright (c) 2026 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Filiaciones:
Gregorc, V:
Ist Candiolo Fdn Piemonte Oncol IRCCS, Candiolo, Italy
Majem, M:
Hosp Santa Creu & St Pau, Barcelona, Spain
Lo Russo, G:
Fdn Irccs Ist Nazl Tumori, Milan, Italy
Maio, M:
Univ Siena, Siena, Italy
Univ Hosp Siena, Ctr Immunooncol, Siena, Italy
Salvagni, S:
IRCCS Azienda Osped Univ Bologna, Bologna, Italy
Gutiérrez-Calderon, V:
Hosp Reg Univ Malaga, Malaga, Spain
Gonzalez-Cao, M:
Hosp Univ Dexeus, Inst Oncol Dr Rosell IOR, Barcelona 08078, Spain
Contreras, SS:
Inst Valenciano Oncol IVO, Valencia, Spain
Koumarianou, A:
Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Athens, Greece
Bearz, A:
IRCCS Ctr Riferimento Oncol, Aviano, Italy
Bernabé-Caro, R:
Hosp Univ Virgen Rocio, Sevilla, Spain
Viteri, S:
Clin Mi Tres Torres, UOMI Canc Ctr, Barcelona, Spain
de Sanmamed, MF:
Clin Univ Navarra, Pamplona, Spain
Zagouri, F:
Alexadra Gen Hosp Athens, Athens, Greece
:
Hosp Univ Germans Trias & Pujol, ICO Badalona, Badalona, Spain
Lazzari, C:
Ist Candiolo Fdn Piemonte Oncol IRCCS, Candiolo, Italy
Martínez-Recio, S:
Hosp Santa Creu & St Pau, Barcelona, Spain
Giménez-Capitán, A:
SA Hosp Univ Dexeus, Pangaea Oncol, Barcelona, Spain
Zhang, Y:
GenFleet Therapeut Shanghai, Shanghai, Peoples R China
Shan, Y:
GenFleet Therapeut Shanghai, Shanghai, Peoples R China
Zhu, HQ:
GenFleet Therapeut Shanghai, Shanghai, Peoples R China
Zhao, CQ:
GenFleet Therapeut Shanghai, Shanghai, Peoples R China
Shen, HG:
GenFleet Therapeut Shanghai, Shanghai, Peoples R China
Wang, Y:
GenFleet Therapeut Shanghai, Shanghai, Peoples R China
Rosell, R:
Hosp Univ Dexeus, Inst Oncol Dr Rosell IOR, Barcelona 08078, Spain
|